AR107426A1 - DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7 - Google Patents

DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7

Info

Publication number
AR107426A1
AR107426A1 ARP170100186A ARP170100186A AR107426A1 AR 107426 A1 AR107426 A1 AR 107426A1 AR P170100186 A ARP170100186 A AR P170100186A AR P170100186 A ARP170100186 A AR P170100186A AR 107426 A1 AR107426 A1 AR 107426A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heterocyclic ring
halogen
cycloalkyl
Prior art date
Application number
ARP170100186A
Other languages
English (en)
Inventor
Katy White
Martin Teall
Stephen Mack
Gemma Liwicki
Anne Goldby
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR107426A1 publication Critical patent/AR107426A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/30Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la terapia de trastornos auditivos y del SNC. Reivindicación 1: Un compuesto de fórmula (1) donde R¹ representa hidroxilo, -CH₂OH, ciano, -SO₂R¹ᵃ, -(CH₂)ₘ-(O)ₙ-R⁵ o (CH₂)ₚNR⁶R⁷; m es 0 ó 1; n es 0 ó 1; p es 0 ó 1; R¹ᵃ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆; cada uno de R² y R³ representa independientemente hidrógeno, halógeno, fluorometilo, difluorometilo, trifluorometilo, metoxi, fluorometoxi, difluorometoxi o trifluorometoxi; cualquier R⁴ᵃ representa (X)ₜ-(CH₂)ᵛ-R¹⁶ o -CH₂O-R¹⁷ y R⁴ᵇ representa hidrógeno, metilo o flúor, o R⁴ᵃ y R⁴ᵇ, junto con el átomo de carbono al cual se acoplan, forman un anillo heterocíclico o carbocíclico saturado de 3 a 6 miembros, donde el anillo heterocíclico comprende al menos un heteroátomo anular que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo carbocíclico o heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, oxo, alquilo C₁₋₃, alcoxi C₁₋₃, amino, metilamino, dimetilamino y haloalquilo C₁₋₃; R⁵ representa un grupo cicloalquilo C₃₋₆, un anillo heterocíclico de 4 a 6 miembros que contiene un heteroátomo anular individual que es un átomo de nitrógeno donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente seleccionado de halógeno, alquilo C₁₋₃ y haloalquilo C₁₋₃ o un grupo alquilo C₁₋₆ que no está sustituido o está sustituido con al menos un sustituyente seleccionado de cicloalquilo C₃₋₆, NR²²R²³ y un anillo heterocíclico saturado de 4 a 6 miembros que comprende al menos un heteroátomo anular que se selecciona de átomos de nitrógeno y oxígeno, donde dicho anillo heterocíclico no está sustituido o está sustituido con halógeno; cada uno de R⁶ y R⁷ representa independientemente hidrógeno, -(CH₂)q-R⁸, -SO₂R⁹, alquilo C₁₋₆, alquilcarbonilo C₁₋₆, cicloalquilcarbonilo C₃₋₆ o alcoxicarbonilo C₁₋₆, donde cada uno de los restos alquilo, cicloalquilo o alcoxi en los últimos cuatro sustituyentes no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, alcoxi C₁₋₄ y -NR¹⁰R¹¹, o R⁶ y R⁷, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado o no saturado de 4 a 7 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de nitrógeno, oxígeno y azufre, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, ciano, alquilo C₁₋₆, cicloalquilo C₃₋₆, cicloalquilmetilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquiloxi C₃₋₆, cicloalquilmetiloxi C₃₋₆ y -NR¹²R¹³; q es 0, 1 ó 2; R⁸ representa un anillo carbocíclico o heterocíclico saturado o no saturado de 3 a 6 miembros donde el anillo heterocíclico comprende de 1 a 4 heteroátomos anulares que se seleccionan independientemente de nitrógeno, oxígeno y azufre, donde el anillo carbocíclico o heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, ciano, alquilo C₁₋₆, cicloalquilo C₃₋₆, cicloalquilmetilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquiloxi C₃₋₆, cicloalquilmetiloxi C₃₋₆ y -NR¹⁴R¹⁵; R⁹ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, cada uno de los cuales no está sustituido o está sustituido con al menos un átomo de halógeno; cada uno de R¹⁰ y R¹¹ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹⁰ y R¹¹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R¹² y R¹³ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹² y R¹³, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R¹⁴ y R¹⁵ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹⁴ y R¹⁵, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; t es 0 ó 1; v es 0, 1 ó 2; R¹⁶ representa -R¹⁷, -NR¹⁸R¹⁹ o un anillo heterocíclico saturado o no saturado de 4 a 6 miembros que comprende de 1 a 4 heteroátomos anulares que se seleccionan independientemente de nitrógeno, oxígeno y azufre, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente seleccionado de oxo, halógeno, ciano, fluorometoxi, difluorometoxi, trifluorometoxi, alquilo C₁₋₆, alcoxi C₁₋₆ y haloalquilo C₁₋₆; X es O, NH, -NHC(O)-, -NHC(O)O-, -C(O)NH-, -NHSO₂- o -SO₂NH-, siempre que cuando X sea O, NH, -C(O)NH- o -SO₂NH- y R¹⁶ represente -NR¹⁸R¹⁹, v sea 2; R¹⁷ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, cada uno de los cuales no está sustituido o está sustituido con al menos un sustituyente que se selecciona de hidroxilo, halógeno y -NR²⁰R²¹; cada uno de R¹⁸ y R¹⁹ representa independientemente hidrógeno, alquilo C₁₋₆, alquilcarbonilo C₁₋₆, cicloalquilcarbonilo C₃₋₆, alquilsulfonilo C₁₋₆ o cicloalquilsulfonilo C₃₋₆, donde cada uno de los restos alquilo o cicloalquilo en los últimos cinco sustituyentes no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alcoxi C₁₋₄, o R¹⁸ y R¹⁹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R²⁰ y R²¹ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R²⁰ y R²¹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; y cada uno de R²² y R²³ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R²² y R²³, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; siempre que el compuesto de fórmula (1) no sea N-[(1S,2S)-1-amino-2,3-dihidro-1H-inden-2-il]-1-(4-fluorofenil)ciclopropano-1-carboxamida; o una sal farmacéuticamente aceptable de este.
ARP170100186A 2016-01-25 2017-01-25 DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7 AR107426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1601301.3A GB201601301D0 (en) 2016-01-25 2016-01-25 Novel compounds

Publications (1)

Publication Number Publication Date
AR107426A1 true AR107426A1 (es) 2018-04-25

Family

ID=55534857

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100186A AR107426A1 (es) 2016-01-25 2017-01-25 DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7

Country Status (25)

Country Link
US (1) US20190031599A1 (es)
EP (1) EP3408256A1 (es)
JP (1) JP2019508390A (es)
KR (1) KR20180108600A (es)
CN (1) CN108602760A (es)
AR (1) AR107426A1 (es)
AU (1) AU2017210803A1 (es)
BR (1) BR112018015247A2 (es)
CA (1) CA3012443A1 (es)
CL (1) CL2018002010A1 (es)
CO (1) CO2018007610A2 (es)
EA (1) EA201891680A1 (es)
EC (1) ECSP18056196A (es)
GB (1) GB201601301D0 (es)
HK (1) HK1257091A1 (es)
MA (1) MA43922A (es)
MX (1) MX2018009078A (es)
PE (1) PE20181333A1 (es)
PH (1) PH12018501563A1 (es)
SG (1) SG11201804899YA (es)
TN (1) TN2018000175A1 (es)
TW (1) TW201733977A (es)
UY (1) UY37084A (es)
WO (1) WO2017131221A1 (es)
ZA (1) ZA201803520B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
CN115667212A (zh) 2020-05-29 2023-01-31 富士胶片富山化学株式会社 高纯度的n-(5-甲氧基-2-苯氧基苯基)甲磺酰胺及其制造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK626889A (da) * 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
CA2138788A1 (en) * 1992-06-22 1994-01-06 Dietrich Arndts Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions
DE4220353A1 (de) * 1992-06-22 1993-12-23 Boehringer Ingelheim Kg Verwendung carbocyclisch und heterocyclisch annelierter Dihydropyridine als Mittel mit antiproliferativer Wirkung
EP1009758B1 (en) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
EP1194400A1 (en) * 1999-06-30 2002-04-10 Prescient Neuropharma Inc. 2-aminoindane analogs
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
DE10108307A1 (de) * 2001-02-21 2002-08-29 Gruenenthal Gmbh Substituierte Propan-1,3-diamin-Derivate
JPWO2002102807A1 (ja) * 2001-06-14 2004-09-30 萬有製薬株式会社 新規イソキサゾロピリドン誘導体及びその用途
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
DK1751131T3 (da) * 2004-03-10 2009-03-16 Janssen Pharmaceutica Nv MTP-inhiberende arylpiperidiner eller -piperaziner, der er substitueret med 5-leddede heterocykler
NZ552979A (en) * 2004-08-09 2010-02-26 Glaxo Group Ltd Indane and tetralin derivatives which potentiate glutamate receptor and uses thereof in medicine
CN101248046A (zh) * 2005-07-11 2008-08-20 德福根有限公司 作为激酶抑制剂的酰胺衍生物
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists

Also Published As

Publication number Publication date
UY37084A (es) 2017-08-31
EA201891680A1 (ru) 2019-01-31
CN108602760A (zh) 2018-09-28
GB201601301D0 (en) 2016-03-09
ZA201803520B (en) 2019-03-27
AU2017210803A1 (en) 2018-07-19
PE20181333A1 (es) 2018-08-20
CO2018007610A2 (es) 2018-07-31
JP2019508390A (ja) 2019-03-28
CA3012443A1 (en) 2017-08-03
BR112018015247A2 (pt) 2018-12-18
MX2018009078A (es) 2018-11-09
PH12018501563A1 (en) 2019-05-15
US20190031599A1 (en) 2019-01-31
HK1257091A1 (zh) 2019-10-11
SG11201804899YA (en) 2018-07-30
KR20180108600A (ko) 2018-10-04
TW201733977A (zh) 2017-10-01
ECSP18056196A (es) 2018-08-31
MA43922A (fr) 2018-12-05
EP3408256A1 (en) 2018-12-05
CL2018002010A1 (es) 2019-03-15
TN2018000175A1 (en) 2019-10-04
WO2017131221A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR110922A1 (es) Compuestos inhibidores del vih
AR126406A2 (es) Compuestos de tetrazolinona y su uso
AR112529A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR093364A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR101208A1 (es) Espirocicloheptanos como inhibidores de rock
AR104513A1 (es) Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR112804A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR094550A1 (es) Inhibidores de btk
AR098492A1 (es) Derivados de purina
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR098436A1 (es) Compuestos tricíclicos de piperidina
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina

Legal Events

Date Code Title Description
FB Suspension of granting procedure